SCM
HRTX icon

Stonepine Capital Management’s Heron Therapeutics HRTX Stock Holding History

Stonepine Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Hold
1,000,000
– – 0.85% 32
2026
Q1 		$800K Buy
+1,000,000
New +$1.16M 0.32% 45

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Stonepine Capital Management's HRTX Position: Q2 2026 in Review

Stonepine Capital Management reduced its Heron Therapeutics (HRTX) stake by 65% in Q2 2026, selling an estimated $731K and leaving 490,787 shares worth $209K. The position accounts for 0.12% of the portfolio, ranked #79.

Stonepine Capital Management first reported a position in HRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.75M in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Stonepine Capital Management held 490,787 shares of Heron Therapeutics worth $209K as of Q2 2026.
  • Stonepine Capital Management sold 911,404 Heron Therapeutics shares in Q2 2026, an estimated $731K.
  • Heron Therapeutics made up 0.12% of Stonepine Capital Management's portfolio in Q2 2026, its #79 holding.
  • Stonepine Capital Management first reported a position in Heron Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Stonepine Capital Management's Heron Therapeutics position peaked at $1.75M in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.